| This week's sponsor is Premier Research. | | | Discovering the Great Potential of Immuno-Oncology Drugs
Immuno-modulating agents have been around a long time, but for limited uses. New immuno-oncology pathways promise big advances against a wider range of cancers. Register now for our May 23 webinar. Premier Research. It's what we do. Best. |
Featured Story | Wednesday, May 17, 2017 The FDA has granted priority review status to Bayer’s copanlisib, setting the PI3K inhibitor up to speed through the regulatory process in six months or less. Bayer secured the privileged position on the strength of data from a mid-phase trial in patients with non-Hodgkin lymphoma. |
|
|
| This week's sponsor is Medpace. | | | |
Top Stories | Wednesday, May 17, 2017 G1 Therapeutics thinks it has a winner on its hands with CDK4/6 inhibitor trilaciclib and is embarking on an initial public offering to give it the resources it needs to bring it to market. |
|
|
| Wednesday, May 17, 2017 AstraZeneca EVP Mene Pangalos has laid out how he wants the next government to support the United Kingdom’s life sciences sector through Brexit. The R&D leader’s wish list to U.K. politicians includes a “welcoming” environment for global talent and a local regulatory agency aligned with the EMA. |
|
|
| Wednesday, May 17, 2017 Johnson & Johnson has listed the pipeline prospects it expects to drive the growth in its biopharma business for years to come. The company is hoping to get 11 potential blockbusters ready for market by 2021, starting with regulatory green lights for psoriasis candidate guselkumab and rheumatoid arthritis prospect sirukumab. |
|
|
| Wednesday, May 17, 2017 Concert Pharmaceuticals' just-started phase 2a trial of its baldness candidate CTP-543 has been halted by an FDA request to look at preclinical toxicity data. |
|
|
| Monday, May 15, 2017 China's FDA is proposing another round of policy changes designed to hasten clinical trial approval and lift restrictions placed on trial sites, with the ultimate goal of allowing drugs to get into the clinic faster. |
|
|
| This week's sponsor is Cmed Research. | | | |
| | | The CEO of Novelion left the Novo Nordisk board over a NASH conflict. Reuters article Conatus Pharmaceuticals completed a public offering to fund the expansion of its pipeline. Statement Merck and Aduro Biotech agreed to test Keytruda in combination with CRS-207. Release | |
|
Resources Presented By: Covance The ICH GCP E6 guideline has been revised to address the complexities associated with today’s clinical trials, and this concise white paper will help you understand the recent guideline changes. Learn how use of risk-based monitoring can help you comply with the guidelines and achieve efficiency in clinical trial design, implementation and reporting. Sponsored By: Veeva To thrive in a fiercely competitive market, life sciences companies need to set themselves apart by designing and executing the best trial and successfully deliver drugs to market first. Learn how a modern EDC can help. Sponsored By Reprints Desk Puzzled by Scientific Literature Access? Here is your guide for navigating knowledge management’s twists and turns! If yours is a small- or medium-sized biopharma business, we can help you putting the pieces together. Learn the secrets of top knowledge management experts who will show you how to search, discover, acquire and manage knowledge in new ways. Presented By: Covance The recent evolution of immunotherapies and their potential applications have greatly impacted patients’ options for effective oncology treatments. These advances have been powered in part by the use of biomarkers, companion diagnostics (CDx) and complementary diagnostics. Read the white paper. Sponsored By: DocuSign DocuSign’s eSignature solutions modernize healthcare and life science organizations by eliminating paper and antiquated signature processes while meeting compliance requirements and reducing costs and errors. Sponsored By: DocuSign The patients who rely on your scientific leadership are expecting more. Sponsored By: DocuSign The U.S. Department of Justice has collected upwards of $17 billion in settlements from the healthcare industry since 2009, including more than $2 billion from a single life sciences company. MIXiii-BIOMED 2017 May 23-25, 2017 | Tel Aviv, Israel 8th Transparency and Aggregate Spend West May 23-24, 2017 | San Diego, CA Life Sciences Event of the Year! DIA 2017 Global Annual Meeting 2017 BIO International Convention: The Largest Global Biotech Partnering Event of the Year June 19-22 | San Diego, CA Rational Combinations 360° in Immuno-Oncology June 28-29, 2017 | New York, NY Drug Development Boot Camp® 2017 November 15-16, 2017 | Boston, MA FierceBiotech Executive Breakfast- Tackling the Drug Price Problem: A Town Hall Debate June 21, 2017 | San Diego, CA FierceBiotech 2nd Drug Development Forum September 25-27, 2017 | Boston, MA | 